回顾百奥赛图IPO之路，公司科创板IPO于2023年6月20日获得受理，于今年9月24日上会通过，并于9月 26日提交注册。 北京商报讯（记者 丁宁）10月16日晚间，上交所官网显示，百奥赛图（北京）医药科技股份有限公司 （以下简称"百奥赛图"）科创板IPO已注册生效。 招股书显示，百奥赛图成立于2009年，是一家临床前CRO以及生物技术企业。公司基于自主开发的基 因编辑技术提供各类创新模式动物以及临床前阶段的医药研发服务，并利用其自主开发的RenMice全人 抗体小鼠平台（包括RenMab、RenLite、RenNano、RenTCR以及RenTCR-mimic多个系列）针对人体内 近千个潜在药物靶点进行规模化药物发现与开发，并将有潜力的抗体分子对外转让、授权或合作开发。 ...

Overview - The global CRO market is projected to reach $90.03 billion by 2024, with the preclinical CRO market accounting for $27.46 billion, representing 30.5% of the total CRO market [1][9]. - The increasing prevalence of chronic diseases and heightened health awareness are driving demand for high-quality biopharmaceutical products and related research services [1][9]. Industry Barriers - The preclinical CRO sector faces significant entry barriers due to the need for experienced professionals and established operational expertise, which new entrants may struggle to acquire quickly [5][6]. - Established CROs typically have over 10 years of experience, making it challenging for newcomers to compete effectively [5]. Market Policies - The pharmaceutical manufacturing industry is a key focus for development in China, supported by various policies aimed at encouraging new drug research and optimizing approval processes [7]. - Recent policies include guidelines for improving drug quality and promoting digital healthcare, creating a favorable environment for the preclinical CRO industry [7]. Industry Chain - The upstream of the preclinical CRO industry includes suppliers of experimental materials, laboratory animals, scientific instruments, and data analysis software [8]. - The primary clients for preclinical CROs are pharmaceutical companies, which outsource research to reduce costs and improve efficiency [8]. Development Status - China's CRO market is expected to reach 89.22 billion yuan in 2024, with a year-on-year growth of 5.19%, and the preclinical CRO market is projected to reach 42.91 billion yuan, growing by 5.74% [9]. - The demand for CRO services is expanding due to the aging population and rising chronic disease rates in China [9]. Competitive Landscape - The global preclinical CRO market is dominated by established companies in the US and Western Europe, with the US holding a significant market share [10][11]. - Domestic companies like WuXi AppTec and Kanglong Chemical are gaining competitive advantages by understanding local regulations and market needs, offering tailored services at lower costs [11]. Representative Domestic Companies - WuXi AppTec reported a total revenue of 39.24 billion yuan in 2024, with a gross profit of 16.02 billion yuan and a gross margin of 40.8% [12]. - YinuoSi achieved a total revenue of 1.142 billion yuan in 2024, with 95.4% of this revenue coming from its non-clinical CRO services [12][13]. Development Trends - Future advancements in AI and big data analytics are expected to enhance drug discovery and toxicology assessments, improving efficiency and accuracy in the preclinical CRO sector [13]. - There will be a growing emphasis on personalized solutions targeting specific diseases or patient groups, necessitating diverse disease models for drug development [13].

New Listings - From September 22 to September 28, one company was listed on the Shanghai Stock Exchange main board, and three companies were listed on the Shenzhen Stock Exchange ChiNext [2] - YouSheng Co., Ltd. is a professional manufacturer of aluminum alloy automotive parts, focusing on lightweight automotive components to enhance the range of electric vehicles and improve fuel efficiency for gasoline vehicles. On its first trading day, the stock price rose by 71.48%, closing at 66.31 CNY per share on September 29, an increase of 43.03% from the issue price of 46.36 CNY, with a total market capitalization of approximately 12.8 billion CNY [3] ChiNext Listings - Shanghai Jianfa Zhixin Medical Technology Group Co., Ltd. engages in direct sales, distribution, and centralized management of hospital consumables. On its first trading day, the stock price surged by 418.58%, closing at 34.12 CNY per share on September 29, a rise of 383.97% from the issue price of 7.05 CNY, with a total market capitalization of around 14.4 billion CNY [4] - Suzhou Huichuan United Power System Co., Ltd. focuses on the R&D, production, sales, and service of core components for electric drive systems and power systems for electric vehicles. The stock price increased by 147.60% on its first day, closing at 32.77 CNY per share on September 29, up 162.58% from the issue price of 12.48 CNY, with a total market capitalization of approximately 78.8 billion CNY [4] - Beijing Wuchuang Ruitong Electric Equipment Co., Ltd. specializes in the R&D, production, and sales of smart distribution equipment. The stock price rose by 190.76% on its first trading day, closing at 58.78 CNY per share on September 29, an increase of 179.90% from the issue price of 21.00 CNY, with a total market capitalization of about 6.5 billion CNY [5] Companies Passing Review - From September 22 to September 28, two companies passed the review on the Shanghai Stock Exchange Sci-Tech Innovation Board, and one company passed the review on the Shenzhen Stock Exchange ChiNext [6] - BaiAo SaiTu is a preclinical CRO and biotechnology company that provides innovative animal models and preclinical drug development services based on its proprietary gene editing technology [7] - MoEr Thread focuses on the R&D, design, and sales of GPUs and related products, having successfully launched four generations of GPU architecture [7] Companies Submitting IPO Applications - One company submitted an IPO application on the Shanghai Stock Exchange Sci-Tech Innovation Board, and one company submitted an application on the Shenzhen Stock Exchange ChiNext from September 22 to September 28 [10] - Anshi Biotechnology is an innovative biopharmaceutical company focusing on oncology and other diseases with significant unmet clinical needs. The company plans to issue no more than 76.0043 million shares, aiming to raise 2.45 billion CNY for new drug R&D and working capital [12] - Zhongsu Co., Ltd. specializes in the R&D, production, and sales of modified engineering plastics, with applications in consumer electronics, energy storage, automotive, and home appliances. The company plans to issue no more than 12.3329 million shares, seeking to raise 645 million CNY for various projects [14] Companies with Terminated Review - From September 22 to September 28, no companies had their listing reviews terminated on either the Shanghai Stock Exchange or the Shenzhen Stock Exchange [16]

Core Viewpoint - Baiaosaitu (Beijing) Pharmaceutical Technology Co., Ltd. is set to return to A-share market after successfully passing the listing review by the Shanghai Stock Exchange, marking its A+H listing strategy [1] Group 1: Company Overview - Baiaosaitu, established in 2009, is a preclinical CRO and biotechnology company that provides innovative model animals and preclinical drug development services based on its proprietary gene editing technology [1] - The company has developed a comprehensive platform that includes gene-edited model animal preparation, innovative model animal breeding and supply, preclinical pharmacology and efficacy evaluation, and antibody drug discovery [1] Group 2: Business Achievements - As of the reporting period, Baiaosaitu has completed over 5,100 customized gene editing projects and developed more than 3,500 types of RenMice and other gene-edited animals and cell line models [2] - The company has established partnerships with numerous renowned biotech and pharmaceutical companies for antibody drug discovery, leveraging its RenMice platform and "thousands of mice, ten thousand antibodies" approach [2] Group 3: Financial Performance - From 2022 to 2024, Baiaosaitu's revenue is projected to be 534 million yuan, 717 million yuan, and 980 million yuan, with a compound annual growth rate of 35.56% [3] - The net profit for the same period is expected to be -602 million yuan, -383 million yuan, and 33.54 million yuan, indicating a turnaround to profitability in 2024 [3] Group 4: IPO and Fundraising - Baiaosaitu plans to raise 1.185 billion yuan through its IPO, which will be directed towards enhancing its existing business and core technologies [3] - The fundraising will support projects aimed at expanding the production capacity of model animals, improving early drug discovery capabilities, and enriching the preclinical research pipeline [3]

Core Viewpoint - The article discusses the recent trend of companies in the A-share market pursuing listings in the Hong Kong stock market, with a specific focus on Bai'ao Saitou (Beijing) Pharmaceutical Technology Co., Ltd. taking a "H first, A later" approach for its IPO [1][3]. Group 1: Company Overview - Bai'ao Saitou is a preclinical CRO enterprise primarily engaged in the sale of experimental mice and is recognized as one of the "three giants of model animals" alongside Yao Kang Biological and Nanmo Biological [3]. - The company achieved profitability, reporting a revenue of 621 million yuan for the first half of 2025, a year-on-year increase of over 50%, and a net profit of 48 million yuan, a significant turnaround from a net loss of 51 million yuan in the same period of 2024 [4]. Group 2: IPO and Financial Disclosures - Bai'ao Saitou's IPO plan aims to raise 1.185 billion yuan, which is over a 30% reduction from its initial application, with funds allocated for the construction of a drug early research service platform, antibody drug research and evaluation, and preclinical research projects [5]. - The company is the first Hong Kong-listed company to apply for the Sci-Tech Innovation Board this year and has been under review for over two years [3][6]. Group 3: Profitability and Revenue Growth - The company reported an expected revenue of 897 million yuan for the first nine months of 2025, reflecting a year-on-year growth of over 50%, with a net profit of 58 million yuan, a significant improvement from a net loss of 93 million yuan in the same period of 2024 [6]. - Bai'ao Saitou's revenue growth is attributed to its model animal sales and antibody development, with model animal sales generating 389 million yuan in 2024, a year-on-year increase of over 40% [13]. - The antibody development business saw even stronger growth, generating 318 million yuan in 2024, a year-on-year increase of over 80% [14]. Group 4: Cost Management - The company has effectively reduced management and research and development expenses, with management costs decreasing by nearly 30% to 187 million yuan and R&D expenses dropping from 474 million yuan in 2023 to 324 million yuan in 2024, a reduction of nearly one-third [17].

Summary of Key Points Core Viewpoint - This week, one new stock will be available for subscription, while four companies are undergoing IPO reviews, indicating ongoing activity in the capital markets [2][3]. Group 1: New Stock Subscription - One new stock, Aomeisen, will be available for subscription on Monday, September 25 [2]. - Last week, Shichang Co. debuted on the North Exchange, experiencing a significant first-day increase of 271.56% [2]. Group 2: Company Performance and Financials - Shichang Co. specializes in the research, production, and sales of automotive fuel systems, primarily selling to major vehicle manufacturers like Geely and FAW [2]. - Baiaosaitu, known as the "first stock in gene editing," plans to raise approximately 11.85 billion yuan for early drug development services and other projects [3][5]. - Baiaosaitu's projected revenues for 2022, 2023, and 2024 are 534 million yuan, 717 million yuan, and 980 million yuan, respectively, with net profits expected to improve from a loss of 602 million yuan in 2022 to a profit of 33.54 million yuan in 2024 [3][4]. Group 3: Fundraising and Investment Plans - The fundraising plan for Baiaosaitu includes allocations of 45.36 million yuan for early drug development services, 31.65 million yuan for antibody drug research, and 16.5 million yuan for preclinical research [6]. - The total investment amount for these projects is 118.5 million yuan, with the majority directed towards early drug development services [6].

4公司IPO上会 值得注意的是，截至目前本周（9月22日到26日）将有4家公司IPO首发上会，为拟闯关科创板IPO的摩 尔线程、百奥赛图；创业板IPO的南网数字以及北交所IPO的蘅东光。 据目前安排，若无变化，本周（9月22日到26日）有1只新股申购。 本周1股打新 截至发稿，本周网上发行的1只新股披露发行价。北交所新股奥美森发行价为8.25元/股，发行市盈率为 12.99倍，行业最近一个月平均动态市盈率为35.86倍。 9月22日启动申购的北交所新股奥美森，是专业的智能装备制造生产商，主要从事智能生产设备及生产 线的研发、设计、生产、销售，公司产品可广泛应用于电器、环保、风电和锂电新能源及其他行业等领 域，是实现生产自动化、智能化和高效化的关键装备。公司主要产品包括换热器生产智能设备、管路加 工智能设备和其他定制智能设备（环保设备、锂电池热压整形设备和风电叶片根部数控铣削机等）。 经过多年的行业积累与发展，奥美森已经与格力电器、美的集团、奥克斯、海信家电、TCL家电、四川 长虹、大金空调、松下电器、江森自控、特灵、开利、富士通将军、三菱重工海尔等国内外家电巨头建 立了稳定的合作关系。随着公司在国内市场中不断 ...

招股书显示，百奥赛图成立于2009年，是一家临床前CRO以及生物技术企业。公司基于自主开发的基 因编辑技术提供各类创新模式动物以及临床前阶段的医药研发服务，并利用其自主开发的RenMice全人 抗体小鼠平台（包括RenMab、RenLite、RenNano、RenTCR以及RenTCR-mimic多个系列）针对人体内 近千个潜在药物靶点进行规模化药物发现与开发，并将有潜力的抗体分子对外转让、授权或合作开发。 北京商报讯（记者 丁宁）上交所官网显示，上交所上市审核委员会定于9月24日召开2025年第38次上市 审核委员会审议会议，审议百奥赛图（北京）医药科技股份有限公司（以下简称"百奥赛图"）的首发事 项，公司科创板IPO于2023年6月20日获得受理。 ...

Core Viewpoint - The company is experiencing a phase of performance pressure due to industry cyclicality, but there are signs of order growth and potential improvement in financial results in the future [3]. Financial Performance - In the first half of 2025, the company achieved operating revenue of 669 million yuan, a year-on-year decline of 21.29%. The net profit attributable to the parent company was 61 million yuan, marking a return to profitability, while the net profit excluding non-recurring items was 23 million yuan, also indicating a return to profitability [1]. - In Q2 2025, the company reported operating revenue of 381 million yuan, a year-on-year decline of 27.32%. The net profit attributable to the parent company was 20 million yuan, down 80.67%, and the net profit excluding non-recurring items was -2.61 million yuan [1]. - The company's non-clinical drug research services generated revenue of 639 million yuan in H1 2025, down 21.07% year-on-year, while clinical services generated 29 million yuan, down 26.82% [2]. Profitability Analysis - The laboratory services segment faced significant profit pressure, contributing a net loss of approximately 970 million yuan in H1 2025, a decline of 537.54% year-on-year, primarily due to increased competition leading to a drop in gross margin (24.03%, down 6.34 percentage points) [2]. - The company’s financial management income contributed approximately 320 million yuan to net profit, while the fair value changes of biological assets contributed about 880 million yuan, likely due to a slight increase in the price of experimental monkeys [2]. Order Trends - The total order amount on hand for the company in H1 2025 was approximately 2.3 billion yuan, showing a recovery from about 2.2 billion yuan in Q1 2025. New orders signed in H1 2025 amounted to approximately 1.02 billion yuan, a significant increase from about 900 million yuan in H1 2024 [2]. International Strategy - The company is focusing on expanding its overseas market, achieving operating revenue of 252 million yuan from international operations in H1 2025, a year-on-year increase of 7.13%, with overseas revenue accounting for 37.69% of total revenue [4]. - Over the past two and a half years, the company has signed nearly 500 foreign application projects, with over 90% being dual submissions in China and the U.S. The company has obtained various international industry qualifications to support its international business [4]. Profit Forecast - The company forecasts operating revenues of 1.812 billion yuan, 2.087 billion yuan, and 2.406 billion yuan for 2025, 2026, and 2027, respectively. The net profits attributable to the parent company are expected to be 230 million yuan, 296 million yuan, and 367 million yuan for the same years, with corresponding diluted EPS of 0.31 yuan, 0.40 yuan, and 0.49 yuan [5].

Investment Rating - The report assigns a "Hold" rating for the stock, indicating that the stock price is expected to fluctuate within ±5% of the benchmark [13]. Core Views - The report highlights that the company's performance is under pressure due to industry cyclicality, but there is a marginal acceleration in order growth, suggesting potential improvement in future financial results [2][3]. - The company is focusing on expanding its overseas market presence, with international revenue showing a year-on-year increase of 7.13% in the first half of 2025, accounting for 37.69% of total revenue [4][5]. Summary by Sections Financial Performance - In the first half of 2025, the company reported total revenue of 669 million yuan, a year-on-year decline of 21.29%. The net profit attributable to the parent company was 61 million yuan, marking a return to profitability [1][2]. - The laboratory services segment experienced a significant decline in profit, with a net loss of approximately 97 million yuan, primarily due to increased competition leading to a drop in gross margin [2]. - The company had an order backlog of approximately 2.3 billion yuan as of the first half of 2025, indicating a recovery from the previous quarter [2]. Market Expansion - The company has signed nearly 500 projects for international submissions over the past two and a half years, with over 90% of these projects being dual submissions in China and the United States [4]. - The internationalization strategy is supported by comprehensive industry qualifications, enabling smooth operations in global markets [4]. Earnings Forecast - The company is projected to achieve revenues of 1.812 billion yuan, 2.087 billion yuan, and 2.406 billion yuan for the years 2025, 2026, and 2027, respectively. The net profit attributable to the parent company is expected to be 230 million yuan, 296 million yuan, and 367 million yuan for the same years [7].